Lilly Looks To Tackle High Lipoprotein(a) Via Gene Editing With Verve
Deal snapshot: Verve will get $60m up front in cash and equity investment from Lilly in exchange for rights to a preclinical base-editing program targeting the LPA gene.
Deal snapshot: Verve will get $60m up front in cash and equity investment from Lilly in exchange for rights to a preclinical base-editing program targeting the LPA gene.